Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.
about
Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma.A Guide to the Economics of Hepatitis C Virus Cure in 2017
P2860
Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Cost-Effectiveness of Direct-A ...... and Hepatocellular Carcinoma.
@en
type
label
Cost-Effectiveness of Direct-A ...... and Hepatocellular Carcinoma.
@en
prefLabel
Cost-Effectiveness of Direct-A ...... and Hepatocellular Carcinoma.
@en
P2093
P2860
P1433
P1476
Cost-Effectiveness of Direct-A ...... and Hepatocellular Carcinoma.
@en
P2093
James G Kahn
James Salazar
Jennifer C Lai
John P Roberts
Michael Volk
Neil Mehta
Varun Saxena
P2860
P304
P356
10.1097/TP.0000000000001605
P577
2017-05-01T00:00:00Z